Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II titration study of BIM 23A760 in carcinoid syndrome
2009-013222-16Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Sep 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of onzigolide in Carcinoid Syndrome (CS), sponsored by Ipsen. Primary endpoint: Overall satisfactory relief of symptoms at 24 weeks. Started Sep 2009; status: terminated.
02
Drugs
onzigolide
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on 2009-013222-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013222-16.